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Background: In preclinical studies, the efficacy of the combination 
of antiangiogenic agents with chemotherapy seems to be dependent 
on the specific cytotoxic agent. We conducted a systematic review 
of the efficacy of bevacizumab in combination with taxane or non-
taxane containing regimens for untreated, nonsquamous non–small-
cell lung cancer patients.
Methods: An extensive search of published clinical trials was 
conducted from electronic databases (MEDLINE, EMBASE, and 
Cochrane) and meeting proceedings using relevant search criteria. 
Phase 2 and randomized trials reporting on the efficacy of bevaci-
zumab combined with taxane or non-taxane regimens were selected. 
A systematic analysis of extracted data was performed using 
Comprehensive Meta-Analysis (Version 2.2) software. Clinical out-
come in patients treated with taxane versus non-taxane regimen was 
compared using point estimates for weighted values of median over-
all survival, progression-free survival, and response rate.
Results: Twenty-nine studies reported between 2005 and 2015 
were eligible. A total of 5890 patients (2767 and 3123 in the tax-
ane and non-taxane groups, respectively) were included. The 
taxane and non-taxane groups were comparable in patient charac-
teristics: median age, 62.8 versus 61.2 years; males, 57% versus 
58%; adenocarcinomas, 83% versus 83%; stage IV, 87% versus 
82%; performance status 0/1- 45/55% versus 41/59%, respectively. 
The weighted median overall survival was 14.4 versus 13.7 months 
(p = 0.5); progression-free survival was 6.93 versus 6.99 months 
(p = 0.61); response rate was 41% versus 39% (p = 0.65) for taxane 
and non-taxane groups.
Conclusions: The outcomes between taxane and non-taxane regi-
mens when given in combination with bevacizumab for patients with 
nonsquamous non–small-cell lung cancer are comparable.
Key Words: bevacizumab, taxanes, systematic review.
(J Thorac Oncol. 2015;10: 1142–1147)
Tumor growth depends on the presence of adequate blood supply. This is driven by an “angiogenic shift” in the bal-
ance of growth factors, favoring proangiogenic growth fac-
tors, such as vascular endothelial growth factor (VEGF).1 
Because of the dependence of tumor survival and growth on 
angiogenesis, blockade of the VEGF pathway has emerged as 
a rational target for therapeutic intervention. Bevacizumab is 
a humanized monoclonal antibody that binds VEGF-A and 
inhibits VEGF receptor (VEGFR) signaling. It is approved 
for the treatment of a variety of malignancies including first-
line treatment of advanced stage nonsquamous non–small-cell 
lung cancer (NSCLC) in combination with carboplatin and 
paclitaxel, although it is also used with other chemotherapy 
doublets in routine clinical practice.
NSCLC remains the most lethal form of cancer, with 
over 150,000 deaths estimated in 2013 in the United States.2 
In patients with NSCLC, the overexpression of VEGF pro-
tein and mRNA levels has been associated with worsened 
survival.3,4 In preclinical studies, cytotoxic agents, such as 
docetaxel, decrease endothelial cell proliferation, thereby 
increasing the efficacy of VEGFR blockade by bevacizumab.5 
Bevacizumab in combination with platinum-based chemother-
apy in chemotherapy naive patients with advanced NSCLC has 
been shown to increase both objective response rates (ORR) 
and progression-free survival (PFS) in phase 3 studies.6–8 The 
E4599 study demonstrated significantly improved median sur-
vival from 10.3 months in the control arm to 12.3 months with 
the addition of bevacizumab to carboplatin and paclitaxel. A 
second trial that randomized patients to the regimen of cis-
platin and gemcitabine with or without bevacizumab revealed 
a modest improvement in PFS, which did not translate into 
survival advantage. Another recent study that compared the 
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combination of carboplatin, pemetrexed, and bevacizumab 
did not demonstrate a survival advantage over carboplatin, 
paclitaxel, and bevacizumab (POINTBREAK study).9 This 
study also included different maintenance strategies between 
the two arms. The patients on the pemetrexed arm received 
both pemetrexed and bevacizumab, whereas the control group 
received bevacizumab monotherapy for maintenance.
The results from recent trials prompted the question of 
whether the enhancement in efficacy of chemotherapy with 
bevacizumab may be dependent on specific chemotherapy 
agents. Indeed, preclinical data indicate that taxanes result 
in release of endothelial progenitor cells, an effect that has 
not been observed with gemcitabine.10 This work provided 
a potential explanation for the lack of survival benefit with 
studies that combined bevacizumab with non-taxane chemo-
therapy agents. To understand this issue better, we performed 
a systematic review of published trials to compare the effi-
cacy of bevacizumab in combination with taxane containing 
regimens versus non-taxane containing regimens in front-line 
setting.
METHODS
Search Strategy
A comprehensive and methodical search of the litera-
ture of electronic databases (Medline, Embase, and Cochrane) 
for studies published between 2005 and 2015 was conducted. 
Applicable terms, such as “bevacizumab and NSCLC,” were 
used with the filters “clinical trial,” “humans,” and “all adult: 
19+ years” for the MEDLINE searches. Relevant abstracts 
were searched and retrieved from the conference proceed-
ings of annual meetings of the American Society of Clinical 
Oncology and from the World Conference on Lung Cancer.
Study Eligibility
The studies were independently reviewed by two of the 
authors (M.B. and R.P.) for eligibility. Trials using bevaci-
zumab in combination with a taxane or non-taxane regimen 
in the front-line setting were included in this analysis. Trials 
were excluded if the taxane or non-taxane containing regimen 
did not include platinum. Trials in the non-taxane arm were 
eligible only if they included standard cytotoxic drugs, such as 
pemetrexed, gemcitabine, vinorelbine, or etoposide in the reg-
imen. Phase 1 trials or trials that enrolled less than 20 patients 
were excluded from the analysis. Studies were included if at 
least one of the outcome measures was extractable in an ana-
lyzable form. All prospective randomized, nonrandomized, 
and single arm studies that met the inclusion criteria were 
identified for the analysis.
Data Extraction and Statistical Analysis
The extracted data included demographics, treatment, 
and clinical outcomes (ORR, overall survival [OS], PFS, and 
toxicities). From trials that investigated multiple treatment 
arms, data were only included from the arms that reported on 
bevacizumab and platinum with taxane or standard non-tax-
ane drug (three drugs regimen) in each group. The outcome 
data extracted for each arm were analyzed using random 
and fixed-effect models and reported as weighted measures. 
Overall grade 3–5 toxicities and the most common toxicity 
were extracted for comparisons between the two groups. All 
analyses were performed using Comprehensive Meta-Analysis 
software (CMA Version 2.2) and SAS statistical package V9.3 
(SAS Institute, Inc., Cary, NC). The comparisons between 
the two arms were conducted based on weighted estimates. 
Two-tailed T-test with a significance level of 0.05 was used for 
all comparisons. Heterogeneity among studies was assessed 
using the I2 test.11
RESULTS
A total of 951 studies were reviewed, and 29 studies 
published between 2005 and 2015 were included in the final 
analysis (Fig. 1). Two of the studies included in this analysis 
reported on both taxane and non-taxane groups.9,12 With the 
exception of two trials13,14 that included docetaxel, all other 
studies in the taxane arm included paclitaxel in the regimen 
in combination with cisplatin or carboplatin. All studies in the 
non-taxane group included pemetrexed or gemcitabine in the 
regimen, except for one trial that included only vinorelbine15 
in the combination. The phase 4 SAiL study included peme-
trexed, gemcitabine, vinorelbine, and etoposide in the plati-
num doublet regimen.12 A total of 5890 patients (2767 and 
3123 in the taxane and non-taxane groups, respectively) were 
included. The most common chemotherapy agents used with 
FIGURE 1.  CONSORT diagram outlining study selection.
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bevacizumab among non-taxane regimens were gemcitabine 
(51%) and pemetrexed (30%). However, 55% of the patients 
who were treated with gemcitabine were part of the SAiL 
study.12
The taxane and non-taxane groups were comparable 
in patient characteristics (Table 1): median age, 62.8 versus 
61.2 years; males, 57% versus 58%, adenocarcinomas, 83% 
versus 83%; stage IV, 87% versus 82%; performance status 
0/1- 45/55% versus 41/59%, respectively.
Efficacy
Due to significant heterogeneity among the studies in 
the taxane and non-taxane arms (I2 = 81% and 74%, respec-
tively, p < 0.0001), a random effect model was employed to 
estimate the pooled ORRs. The weighted pooled ORR for the 
taxane arm (N = 1973) was 41% (confidence interval [CI]: 
36–47%; Fig. 2), and that for the non-taxane arm (N = 1706) 
was 39% (CI: 33–44%); p = 0.65. The weighted mean of the 
overall median survival time was estimated and compared 
from the studies that reported the data; the median survival 
was 14.4 months with taxanes (N = 2741) and 13.7 months 
with non-taxanes (N = 3032; p = 0.5).
The weighted mean of the PFS time was compared 
between the two arms from the studies that reported the data; 
the median PFS was 6.93 months with taxanes (N = 2767) and 
6.99 months with non-taxanes (N = 3078; p = 0.61).
There were no significant differences in OS and PFS 
when the taxane group was compared separately with peme-
trexed (N = 823; OS: 14.4 versus 13.2 months, p = 0.50; PFS: 
6.93 versus 6.6 months, p = 0.40) and gemcitabine (N = 743; 
OS: 14.4 versus 13.4 months, p = 0.66; PFS: 6.93 versus 6.73 
months, p = 0.59) based studies. However, the response rate 
(RR) in the gemcitabine group was lower than that of the tax-
ane group (29% versus 41%, p = 0.06) and significantly lower 
than that of the pemetrexed based group in the non-taxane arm 
(29% versus 45%, p = 0.03). The RR was comparable between 
taxane and pemetrexed groups (41% versus 45%, p = 0.5).
Among studies that reported rates of grade 3–5 toxici-
ties, rates were estimated to be lower in the taxane group than 
the non-taxane group (59% CI: 51–66% versus 69% CI: 63–
75%; p = 0.10). Neutropenia was reported as the most com-
mon toxicity in the taxane group with a higher proportion than 
in the non-taxane group (36% CI: 27–46% versus 27% CI: 
19–36%; p = 0.26). However, the differences were not statisti-
cally significant.
In a subset analysis of only phase 2 and 3 studies 
(excluding the phase 4 SAiL study), OS was similar between 
taxane (N = 1947) and non-taxane (N = 1615) groups (13.9 
versus 13.4 months, p = 0.83). Similar analysis of PFS showed 
no difference between the taxane (N = 1973) and non-taxane 
(N = 1661) groups (6.3 versus 6.6 months, p = 0.85).
DISCUSSION
Following the approval of bevacizumab for the treat-
ment of advanced nonsquamous NSCLC by the FDA in 2006, 
a number of efforts have been undertaken to optimize utili-
zation of this agent. The search for predictive biomarkers by 
studying circulating endothelial cells, tumor expression of 
angiogenic markers, novel imaging methods, etc. has been 
unsuccessful to date. There is a great interest in understanding 
the optimal patient population and setting in which bevaci-
zumab should be used in advanced NSCLC.
We sought to understand the role of specific chemother-
apy partners in impacting the outcome of bevacizumab-based 
therapy. In a series of elegant preclinical experiments, Shaked 
et al.10 demonstrated that certain chemotherapy drugs, such as 
taxanes, induce the release of circulating endothelial progeni-
tor cells that are proangiogenic. Pretreatment of mice with 
antiangiogenic agents abrogated the taxane-induced release 
of endothelial progenitor cells. This observation was, how-
ever, not seen with gemcitabine, another often used cyto-
toxic agent in NSCLC therapy. Although taxanes including 
paclitaxel, nab-paclitaxel, and docetaxel are often used for 
the treatment of advanced NSCLC, pemetrexed, gemcitabine, 
and vinorelbine are also effective agents that are part of the 
therapeutic armamentarium. The purpose of our systematic 
analysis of this issue was to determine whether the therapeu-
tic benefit with bevacizumab is restricted to certain combina-
tion partners.
Inclusion of nearly 6000 subjects treated with beva-
cizumab in this analysis provides for a robust database to 
inquire about the role of specific chemotherapy agents. The 
representation of patients treated with taxane and non-taxane 
regimens was comparable. We found that RR, PFS, and OS 
were similar for the combination of bevacizumab with tax-
ane and non-taxane regimens. An inherent limitation of such 
retrospective analyses of published data is the heterogeneity 
among the studies because of the variability of patient popula-
tions included, varying chemotherapy dose and schedules and 
differences in study designs. Another limitation of this study 
is that nearly 50% of patients (including 899 patients reported 
in the phase 4 SAiL study12) in the non-taxane arm received 
bevacizumab in combination with platinum and gemcitabine. 
Given the recent knowledge regarding the role of histology 
in sensitivity to various chemotherapy agents, gemcitabine 
is not the preferred agent for the treatment of nonsquamous 
histology. On the other hand, pemetrexed, which is effica-
cious in nonsquamous histology, only constituted 31% of the 
non-taxane group. In this limited set, we found no difference 
between efficacy with pemetrexed-based and taxane-based 
bevacizumab combinations. However, our analyses showed 
a significantly higher RR with pemetrexed-based studies 
when compared with gemcitabine-based studies within the 
non-taxane group (45% versus 29%, p = 0.03). Our subgroup 
analyses without the SAiL study data also demonstrated com-
parable efficacy between the taxane and non-taxane groups. 
Our results are aligned with the data from the POINTBREAK 
study, which was designed to demonstrate an improvement in 
survival with the carboplatin, pemetrexed, and bevacizumab 
regimen over the carboplatin, paclitaxel, and bevacizumab 
regimen. There was no improvement in OS, and the median 
survival was comparable between the two arms. Although the 
primary issue in this study was to compare pemetrexed with 
paclitaxel in nonsquamous histology, it can also be gleaned 
that the outcomes with the addition of bevacizumab were not 
influenced by one chemotherapy or the other.
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From this analysis, we conclude that the efficacy of 
bevacizumab appears to be comparable when used with 
either a taxane-based or a non-taxane-based combina-
tion regimen in advanced nonsquamous NSCLC. The most 
important fact remains that for agents that add a relatively 
modest efficacy to existing therapies, the absence of a bio-
marker to identify sensitive populations is a major hurdle for 
optimal utilization.
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